According to Zacks, “Balchem Corporation provides state-of-the-art solutions and the finest quality products for a range of industries worldwide. Balchem Company consists of four business segments: Human Nutrition & Health; Animal Nutrition & Health; Specialty Products; and Industrial Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. The Industrial Products segment manufactures and supplies certain derivative products into industrial applications. “
Several other equities research analysts also recently weighed in on the stock. BidaskClub downgraded shares of Balchem from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 31st. ValuEngine raised shares of Balchem from a “sell” rating to a “hold” rating in a research report on Thursday, April 2nd. Finally, HC Wainwright decreased their target price on shares of Balchem from $122.00 to $116.00 and set a “buy” rating for the company in a research report on Monday, February 24th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $109.67.
Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Friday, February 21st. The basic materials company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.04. Balchem had a net margin of 12.38% and a return on equity of 14.20%. The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $165.55 million. During the same period in the previous year, the firm posted $0.77 earnings per share. The business’s revenue was up 1.8% compared to the same quarter last year. On average, equities analysts anticipate that Balchem will post 2.57 EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the stock. Archer Investment Corp bought a new position in shares of Balchem during the 4th quarter valued at $33,000. Carolina Wealth Advisors LLC bought a new position in shares of Balchem during the 4th quarter valued at $56,000. Quantbot Technologies LP bought a new position in shares of Balchem during the 4th quarter valued at $91,000. Capital Analysts LLC grew its holdings in shares of Balchem by 6.3% during the 4th quarter. Capital Analysts LLC now owns 2,125 shares of the basic materials company’s stock valued at $216,000 after purchasing an additional 125 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Balchem by 8.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,167 shares of the basic materials company’s stock valued at $220,000 after purchasing an additional 168 shares during the last quarter. 87.79% of the stock is currently owned by institutional investors.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Recommended Story: Market Timing – The Benefits and the Danger
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.